Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
determination of the effectiveness and the cost-effectiveness of simvastatin(Zocor 40 mg)
plus standard therapy (SSCG)versus standard therapy alone in critically ill septic patient
from the societal perspective over one year.